Preclinical News and Research

RSS

New experimental device effectively removes blood clots in stroke patients

An experimental device for removing blood clots in stroke patients dramatically outperformed the standard mechanical treatment, according to research presented by UCLA Stroke Center director Dr. Jeffrey L. Saver at the American Stroke Association's 2012 international conference in New Orleans on Feb. 3.

4 Feb 2012

EUSA Pharma acquires ASPAREC development and commercialization rights

EUSA Pharma, a transatlantic specialty pharmaceutical company focused on oncology, oncology supportive care and critical care, today announced that it has acquired the exclusive worldwide development and commercialization rights to ASPAREC for the treatment of acute lymphoblastic leukemia (ALL) from Alizé Pharma.

3 Feb 2012

USF receives DOD grant for battlefield-related TBI research

The University of South Florida (USF) has received a $1.57 million U.S. Department of Defense grant to conduct translational research on traumatic brain injury and other battlefield related injuries and diseases.

2 Feb 2012

Affinium initiates AFN-1252 Phase 2 trial in acute bacterial skin & skin structure infections

Affinium Pharmaceuticals announced today dosing of the first patient in a multi-center Phase 2 clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections.

1 Feb 2012

Potential way to block second wave of death from pneumonia treatment

An international research team may have found a way to block a second wave of death that can result from pneumonia treatment.

1 Feb 2012

NanoViricides files FluCide pre-IND briefing document with the FDA

NanoViricides, Inc. announced today that it has submitted a pre-IND briefing document to the US FDA. This submission provides the required information for the Company's highly effective anti-influenza drug candidate, FluCide, in support of a pre-IND Meeting.

1 Feb 2012

Dana-Farber receives MLSC grant to expand cancer imaging research

The Massachusetts Life Sciences Center has awarded Dana-Farber Cancer Institute a $10 million grant to support the expansion of its pioneering cancer imaging research program.

1 Feb 2012

CartiHeal secures $5M in venture funding

CartiHeal (2009), Ltd, a privately held medical device company, focused on developing and bringing to market a proprietary, off-the-shelf, and cell-free cartilage regeneration technology, announced that it raised $5 million in venture funding from two US-Israeli venture capital firms, Accelmed and Access Medical Ventures. The financing will be used to prepare its first product launch early 2013 in Europe.

1 Feb 2012

Scientists identify TDO enzyme as new target for cancer therapy

Scientists from the Ludwig Institute for Cancer Research (LICR) in Brussels identified a new target for cancer therapy, an enzyme which prevents the immune system from recognizing and destroying certain types of tumors.

1 Feb 2012

New combination clinical trial may improve outcome for cancer surgery patients

The week before and two weeks after surgery are a critical period for the long-term survival rate of cancer patients. Physiological and psychological stresses caused by the surgery itself can inhibit the body's immune responses, heightening vulnerability to tumor progression and spreading.

1 Feb 2012

Milestone for Starpharma's drug delivery program

Starpharma Holdings today released animal data which demonstrated that its dendrimer-docetaxel formulation applying Starpharma’s dendrimer technology to the leading chemotherapy drug docetaxel was significantly more efficacious than docetaxel (Taxotere®) in a breast cancer model.

1 Feb 2012

Breast cancer survivors use at-home method to prep their breasts for reconstruction

NewYork-Presbyterian Hospital/Columbia University Medical Center is the first hospital in the New York metro area to offer breast cancer survivors an at-home method for tissue expansion in preparation for breast reconstruction surgery. Patients use a remote control to gradually create a space within their chest wall for a breast implant.

31 Jan 2012

For stroke prevention, large medical centers may have the edge

Despite advances in the diagnosis and treatment of unruptured brain aneurysms, outcomes have remained stagnant over the last 10 years. This can be explained by the dramatic proliferation of minimally invasive endoscopic coiling procedures at lower-volume community hospitals, where outcomes are inferior.

30 Jan 2012

KineMed, Pfizer enter research collaboration on metabolic diseases

KineMed, Inc. today announced a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes.

30 Jan 2012

Circadian's VGX-100 human antibody improves corneal graft survival

Circadian Technologies Limited announced today the publication of data in the scientific journal, Investigative Ophthalmology & Visual Science (IOVS), showing that VEGF-C expression is markedly up-regulated in corneal graft rejection.

30 Jan 2012

Susan Mallery finds breakthrough treatment for oral cancer

Dr. Susan Mallery, a professor in the College of Dentistry at The Ohio State University and Oral Pathology Consultant at the Ohio State University and James Cancer hospitals, has dedicated her nearly 30-year career to studying new strategies to preventing oral cancer.

30 Jan 2012

Scientists develop new vaccine to treat cancer at pre-clinical level

Scientists in Trinity College Dublin, Ireland, have developed a new vaccine to treat cancer at the pre-clinical level. The research team led by Professor Kingston Mills, Professor of Experimental Immunology at Trinity College Dublin discovered a new approach for treating the disease based on manipulating the immune response to malignant tumours.

27 Jan 2012

Scientists evaluate growth, differentiation and function of iPSC-derived NPCs in PD

Induced pluripotent stem cells (iPSC) are a promising avenue for cell replacement therapy in neurologic diseases. For example, mouse and human iPSCs have been used to generate dopaminergic (DA) neurons that improve symptoms in rat Parkinson's disease models. Reporting in the current issue of the Journal of Parkinson's Disease, a group of scientists from Japan evaluated the growth, differentiation, and function of human-derived iPSC-derived neural progenitor cells (NPCs) in a primate model, elucidating their therapeutic potential.

25 Jan 2012

Prosensa secures €23M in new equity financing

Prosensa, the Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet needs, announced today that it has raised €23 million in new equity financing.

25 Jan 2012

Cohera receives FDA IDE approval to initiate U.S. clinical study for TissuGlu

Cohera Medical, Inc., a leading innovator and developer of absorbable surgical adhesives and sealants, announced today that it has received Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration ("FDA") to begin a prospective, multicenter, randomized clinical trial for its lead product, TissuGlu Surgical Adhesive in the United States.

25 Jan 2012